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Background: In oncology, establishing the value of new cancer treatments is challenging. 
A clear definition of the different perspectives regarding the drivers of innovation in oncology is 
required to enable new cancer treatments to be properly rewarded for the value they create. The 
aim of this study was to analyze the views of oncologists, health care policy makers, patients, 
and the general population regarding the value of new cancer treatments.
Methods: An exploratory and qualitative study was conducted through structured interviews 
to assess participants’ attitudes toward cost and outcomes of cancer drugs. First, the participants 
were asked to indicate the minimum survival benefit that a new treatment should have to be 
funded by the Spanish National Health System (NHS). Second, the participants were requested 
to state the highest cost that the NHS could afford for a medication that increases a patient’s 
quality of life (QoL) by twofold with no changes in survival. The responses were used to cal-
culate incremental cost-effectiveness ratios (ICERs).
Results: The minimum improvement in patient survival means that justified inclusions into 
the NHS were 5.7, 8.2, 9.1, and 10.4 months, which implied different ICERs for oncologists 
(€106,000/quality-adjusted life year [QALY]), patients (€73,520/QALY), the general population 
(€66,074/QALY), and health care policy makers (€57,471/QALY), respectively. The costs stated 
in the QoL-enhancing scenario were €33,167, €30,200, €26,000, and €17,040, which resulted 
in ICERs of €82,917/QALY for patients, €75,500/QALY for the general population, €65,000/
QALY for oncologists, and €42,600/QALY for health care policy makers, respectively.
Conclusion: All estimated ICER values were higher than the thresholds previously described 
in the literature. Oncologists most valued gains in survival, whereas patients assigned a higher 
monetary value to treatments that enhanced QoL. Health care policy makers were less likely to 
pay more for therapeutic improvements compared to the remaining participants.
Keywords: oncology, cost, cost-effectiveness, cost-effectiveness threshold, ICER, clinically 
meaningful outcomes, Spain
Background
Cancer is one of the leading causes of mortality and morbidity worldwide, contributing 
to 8.2 million deaths in 20121 and an estimated 169.3 million years of healthy life 
lost.2 Despite the considerable burden of this disease, important advances in cancer 
prevention, early diagnosis, screening, and treatment have reduced the overall mortality 
associated with this disease. Remarkable progress toward prolonging survival and 
reducing adverse events has been achieved through pharmaceutical treatments that can 
be translated into quality of life (QoL) improvements and potential cost savings.3,4
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Improving health and controlling rising health care costs 
are top priorities for most health care systems. In the current 
health care environment, which is driven by cost-containment 
measures, new cancer treatments that provide lifespan exten-
sion and/or QoL improvement have raised concerns regarding 
whether National Health Systems (NHS) can afford these 
therapeutic advances. The cost-effectiveness ratios of new 
cancer treatments have been scrutinized, given the trend of 
increasing costs of recently approved cancer drugs.5
Knowledge regarding cost-effectiveness helps to estab-
lish the monetary value of new treatments and influence 
the decisions of oncologists and health policy makers. 
In a cost-effectiveness analysis, the additional consump-
tion of medical resources is divided by the health benefits 
(eg, quality-adjusted life years [QALYs]) gained from 
health care interventions to calculate the incremental cost-
effectiveness ratio (ICER). In general, an intervention is 
considered cost-effective if the ICER (cost per QALY) is 
below a predetermined threshold. For instance, common 
thresholds used in reimbursement and coverage decisions 
are £20,000–£30,000/QALY for the UK,6 $50,000/QALY 
for the USA,7 and €30,000/QALY for Spain.8
Decisions regarding rationing and allocating scarce health 
care resources should reflect the society’s opinion regard-
ing willingness to pay for the value that the interventions 
produce.9 In oncology, establishing the value of new cancer 
treatments is challenging. Although some recent advances in 
defining clinically meaningful outcomes for some types of 
cancer have been made,10 a clear definition of the different 
perspectives regarding the drivers of innovation in oncology 
is required to enable new cancer treatments to be properly 
rewarded for the value they create.
Thus far, few studies have analyzed the views of doctors 
and/or health care policy makers regarding the willingness to 
pay for new cancer treatments based on the analysis of their 
potential health benefits.11–14 Some studies have determined the 
implicit ICERs set by oncologists to determine whether a new 
treatment is efficient.15–18 To our knowledge, this study is the 
first to incorporate the perceptions of costs and outcomes for 
other agents that may influence the decision-making process 
and that also represent the interests of society as a whole.
Spain’s NHS represents a publicly funded system that 
offers universal public health care coverage to Spanish 
citizens. Most oncology drugs are administered at hospitals 
and provided free of charge to patients. We conducted an 
exploratory and qualitative study to describe the attitudes 
of oncologists, health care policy makers, patients, and the 
general population toward costs and outcomes of cancer 
drugs in Spain to understand their perceptions regarding the 
costs and value of new cancer agents.
Methods
study participants
All study participants were selected using a nonprobabi-
listic sampling method. Oncologists with a work experi-
ence .10 years and working for the Spanish NHS were 
invited to participate in the study. Health care policy makers 
with at least a single experience of political and legislative 
and local, regional, or national activity were contacted. 
Patient contact was made through local cancer associations 
and through the Spanish Cancer Federation. All participants 
who were invited to participate in the study expressed a clear 
interest in the subject of the study. In order to obtain the 
number of participants required within the established period 
and to assure that all participants were able to understand the 
questionnaire and willing to participate in the study, a conve-
nience sample of the general population was used. This sample 
included employees of technological companies, research 
institutes, universities, and governmental institutions.
All participants were assured of their anonymity and 
confidentiality, and no incentives were offered to any of the 
participants for completing the questionnaire. This study 
followed the principles of the Declaration of Helsinki. Given 
the nature of the study it did not require an ethics committee 
approval.
structured interview
Two hypothetical decision-making scenarios frequently 
presented in oncology clinical practice were included in the 
structured interview: a life-prolonging scenario (scenario 1) 
and a QoL-enhancing scenario (scenario 2). Illustrative 
vignettes were used for both scenarios in order to facilitate the 
understanding of each question. During the interview, general 
information about the respondents was also collected.
The structured interview was carried out between 
December 2013 and February 2014.
Description of the scenarios
To allow comparison with findings from other studies, the 
life-prolonging scenario followed an approach similar to 
that described by Nadler et al.15 Participants had to address a 
hypothetical situation in which a new drug for metastatic lung 
cancer had an additional cost of €50,000 per year compared 
to the standard treatment. Specifically, the standard treatment 
had a cost of €25,000, and the new treatment had a cost of 
€75,000; both treatments had the same safety profile. The 
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standard treatment would provide a 1-year survival rate with-
out changing the health-related QoL. Then, the respondents 
were asked to identify the minimum survival benefit that 
the new treatment should provide to be funded by the NHS. 
Survival benefits were presented in a list that included the 
following options: 1 day, 1 month, 2–4 months, 4–6 months, 
9–12 months, or .12 months.
In the QoL-enhancing scenario, respondents had to 
decide regarding a new treatment for metastatic lung cancer 
that improved the QoL by twofold, from 40 to 80 (on a scale 
from 0 to 100), compared to the standard treatment. Both 
treatments would provide the same efficacy (1 year), and the 
annual cost was €25,000 for the standard treatment. Partici-
pants were asked to establish the additional cost that the new 
treatment should have to be funded by the NHS. Selections 
were made from a list that contained the following values: 
€0, up to €2,000/year, up to €4,000/year, up to €6,000/year, 
up to €10,000/year, up to €20,000/year, up to €50,000/year, 
and .€50,000/year.
Data analysis
In order to understand the different perceptions regarding 
the value and benefit of a new cancer drug considered by 
oncologists, health care policy makers, patients, and the 
general population, the ICER implied by each participant in 
every hypothetical scenario was calculated.
The results were analyzed in a descriptive form. Data anal-
ysis was performed using SPSS v.19 software. The ICER was 
calculated for each respondent using the following formula:
 
ICER
Cost
QALY
= ∆
∆  
(1)
The following is a hypothetical example for the life-
prolonging scenario (scenario 1):
ΔCost =  €50,000 per year (€75,000 for the new treatment − 
€25,000 for the standard treatment) (2)
ΔQALY = (life expectancy [in years] * QoL) for the new 
treatment − (life expectancy [in years] * QoL) for the standard 
treatment. For the life expectancy calculation of the QALY 
term, the midpoint of the selected survival benefit range was 
used and converted into years. No calculations were made 
for the QoL component of the QALY term because the QoL 
in the scenario presented did not change, and as reported 
previously by Nadler et al,15 quality adjustment =1 when 
there was no change in QoL.
For instance, assuming that the respondent selected the 
4- to 6-month range, the calculation would be as follows:
 
€ €50,000ICER 120,000/QALY
5
QALYs
12
= =
 
  
 
(3)
A hypothetical response of €50,000 for the QoL-enhancing 
scenario (scenario 2) in which the new treatment increased 
the QoL by twofold (from 0.4 to 0.8), with the same life 
expectancy for both treatments (1 year), would yield the 
following ICER:
 
€ €50,000ICER 125,000/QALY
0.4 QALYs
= =
 
(4)
Results
Participant characteristics
A total of 53 oncologists, 25 health care policy makers, 
60 patients, and 50 individuals from the general population 
participated in the study. Most of the general population 
participants (88%) were employed; 38% of the general 
population indicated that their annual per capita income was 
€9,500–16,000/year, and 34% answered that their annual per 
capita income was €16,000–30,000/year. The respondent 
characteristics are shown in Table 1.
Table 1 Description of study participants
Characteristics Oncologists 
(n=53)
Health care policy 
makers (n=25)
Patients 
(n=60)
General population 
(n=50)
number contacted 425 140 210 420
response rate (%) 12.5 17.9 28.6 11.9
Agreed to participate 53 25 60 50
Age (years ± sD) 46±9 43±11 49±9 37±10
Age (range) 27–66 26–58 29–71 21–63
sex (female) 47% 56% 95% 52%
Abbreviation: sD, standard deviation.
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incremental cost-effectiveness ratios
scenario 1: life-prolonging scenario
Table 2 describes the responses of participants to the life-
prolonging scenario. The results revealed differences among 
the participants in the minimum mean survival benefit that 
would justify an incremental cost of €50,000 for a new 
cancer treatment, with a range from 5.7 months in the case 
of oncologists to 10.4 months for health care policy makers. 
Consequently, the ICERs implied by these responses differed 
among the participants, resulting in values of €57,471/QALY 
for health care policy makers and €106,000/QALY for oncol-
ogists. Implicit ICER values decreased in the following order 
among the groups of participants: oncologists . patients . 
general population . health care policy makers.
scenario 2: quality of life-enhancing scenario
In the QoL-enhancing scenario, the mean willingness to pay 
for a new drug that improves the QoL by twofold ranged 
from €17,040 in the case of health care policy makers to 
€33,167 for patients (Table 3). These mean values yielded 
ICER values that varied from €42,600/QALY for health 
care policy makers to €82,917/QALY for patients. The 
results based on the ICER data decreased among the groups 
of participants in the following order: patients . general 
population . oncologists . health care policy makers.
Discussion
To the best of our knowledge, this is the first exploratory and 
qualitative study that describes the implicit ICERs suggested 
by oncologists, health care policy makers, patients, and the 
general population for new cancer treatments. Two different 
scenarios, a life-prolonging and a QoL-enhancing scenario, 
were developed to examine whether each of the four groups 
of participants valued a gain in survival or an improvement 
in QoL more based on their willingness to pay for specific 
outcomes. We were also able to detect variations in the 
responses within a specific scenario.
In both scenarios, the ICER values were higher than the 
figures commonly used as thresholds for cost-effectiveness 
analyses.6–8 The higher ICERs obtained in our study may 
indicate that actual reimbursement and access decisions 
may not properly reflect the society’s willingness to pay for 
health benefits. However, the results obtained in this study 
must be confirmed by larger studies. Although conventional 
cost-effectiveness thresholds are often used as a guide to 
interpret the cost-effectiveness analysis, their scientific basis 
has been questioned because these thresholds may not reflect 
the society’s willingness to pay for health benefits and in most 
of the cases have not been updated since their inception.19 
An intense debate regarding whether cost-effectiveness 
thresholds should be reviewed to reflect societal preferences 
has been ongoing since the last decade.20,21 A recent study 
indicated that the threshold should be lowered to £18,317 per 
QALY;22 however, some organizations, including the World 
Health Organization, have pushed for a threshold of two 
to three times the per capita annual income, which would 
represent a threshold of $110,000–$160,000 per QALY for 
the USA.23 In Spain, this threshold would represent a value 
of €44,600–€66,800 per QALY, given the annual per capita 
income of €22,279 in 2013. In our study, the obtained ICERs 
were above the cost–utility ratios published in the literature 
for cancer, which ranged from $27,000 to $48,000 per QALY 
(values for 2008), depending on the tumor type.24
Analyzing both scenarios together showed that oncolo-
gists and health care policy makers presented higher ICER 
values in the life-prolonging scenario compared with those 
in the QoL-enhancing scenario. Conversely, patients and 
the general population yielded higher ICER values in 
the QoL-enhancing scenario compared with those in the 
life-prolonging scenario. These findings may indicate the 
preferences of oncologists and health care policy makers 
to reward survival benefits versus QoL improvements, 
whereas patients and the general population value an 
improvement in the QoL related to cancer treatment more 
than a survival gain.
Table 2 Scenario 1: minimum added survival that justifies an 
incremental cost of €50,000. Mean value expressed by type of 
participants and calculated icer
Participants Mean survival benefit 
(month ± SD)
ICER 
(€/QALY ± SD)
Oncologists 5.7±3.6 106,000±169,265
health care policy 
makers
10.4±2.2 57,471±269,272
Patients 8.2±4.3 73,520±137,127
general population 9.1±4.1 66,074±145,123
Abbreviations: icer, incremental cost-effectiveness ratio; sD, standard deviation; 
QAlY, quality-adjusted life year.
Table 3 scenario 2: accepted additional cost for a treatment that 
improves the Qol (40–80 in a 0–100 scale) twofold. Mean value 
expressed by the type of participants and by the calculated icer
Participants Mean additional 
cost (€ ± SD)
ICER 
(€/QALY ± SD)
Oncologists 26,000±18,876 65,000±47,190
health care policy 
makers
17,040±12,016 42,600±30,039
Patients 33,167±20,589 82,917±51,472
general population 30,200±20,652 75,500±51,629
Abbreviations: Qol, quality of life; icer, incremental cost-effectiveness ratio; 
sD, standard deviation; QAlY, quality-adjusted life year.
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In the life-prolonging scenario, oncologists most valued 
gains in survival, followed by patients, the general popula-
tion, and health care policy makers. These results endorsed 
a cost-effectiveness threshold of €106,000 per QALY for 
oncologists, which was the highest threshold in our study. 
The implicit ICER assessed by oncologists is consistent 
with previous studies examining the views of medical 
oncologists regarding the cost of new cancer medications.15–18 
Ubel et al indicated that oncologists required an average of 
six additional months of life for a cancer drug that costs 
$75,000, which implied an ICER of $100,000 per QALY, 
and 7.8 months for a drug that costs $150,000, suggesting an 
ICER of $192,308 per QALY.17 In a study performed in the 
USA by Nadler et al, the mean implied cost-effectiveness 
ratio reported by oncologists for a new cancer drug that 
provides a survival benefit was $318,773.15 Camps-Herrero 
et al estimated the cost per QALY that could be adopted 
in the field of oncology in Spain based on the opinions of 
35 experts and determined that 68.8% of the respondents 
considered a cost per QALY between €30,000 and €100,000 
to be acceptable.25
Our study found that the ICERs for patients and the gen-
eral population for the QoL scenario were among the highest 
compared to those for oncologists and health care policy 
makers. Compared to the other groups of participants, 
patients were willing to pay more for a twofold improvement 
in QoL. These results are particularly relevant for the current 
era of patient-centered medicine, in which the preferences 
of patients for a specific treatment should be considered 
during the decision-making process.26 For a comprehensive 
evaluation of treatment efficacy, a patient-reported outcome 
assessment should be included to fully capture patients’ per-
ceptions of symptoms, functioning, and general well-being.27 
In oncology, patient-reported outcome measures still have 
little effect on the decision-making process, in which the 
primary endpoints of survival usually drive reimbursement 
decisions. Similar to the results of the present study, where 
patients and the general population placed greater importance 
on the QoL-enhancing scenario than on the life-prolonging 
treatment scenario, a recent study suggested that end-of-life 
(EOL) decisions made by cancer patients and their caregivers 
were significantly affected by their preference for QoL over 
quantity of life, whereas the decisions made by physicians 
were not.28
The comparison of both scenarios shows that oncolo-
gists placed a significantly higher value per QALY on life-
prolonging treatment than on QoL-enhancing interventions 
in our study. This finding may reflect traditional approaches 
to medical ethics based on the principle of beneficence, 
which requires medical professionals to treat patients in a 
manner that produces the maximum benefit for the patient, 
resulting in the prioritizing of survival gains versus QoL 
improvements. In the literature, studies that examined both 
survival gains and QoL improvements showed that estimated 
ICERs related to gains in survival were also greater compared 
with those estimated in QoL-enhancing scenarios.16,18 For 
the two scenarios analyzed in our study, health care policy 
makers were less willing to pay for therapeutic improve-
ments compared to the remaining participants. This finding 
was somewhat anticipated because of their responsibility in 
financing and delivering health care, particularly in Spain, 
where cancer treatments are publicly funded and exempted 
from copayment by the patient. This situation may contrast 
with other country settings in which out-of-pocket costs may 
influence treatment recommendations.
The results of this study have several implications and 
they highlight that the implicit cost-effectiveness thresholds 
varied widely across oncologists, health care policy makers, 
patients, and the general population, reflecting a lack of 
consensus about this issue.
Nowadays, understanding the value that these individuals 
place on innovation of new cancer drugs and their willingness 
to pay for them is becoming more important since it may 
enrich the discussion related to cost-effectiveness threshold 
and its implications.
Given that the market price depends in part on the willing-
ness of third-party payers to reimburse treatment, the lower 
ICER awarded by health care policy makers may have an 
influence on the pricing of new cancer drugs.
Results also reflect that although oncologists are aware 
of the cost of new cancer drugs, it does not necessarily affect 
their decision-making process related to prescription.
When drugs offer the potential to increase the survival 
or improve the QoL, refusing to fund these drugs is politi-
cally difficult.29 Oncology is one of the exclusive therapeutic 
areas in which exceptions are being made to bring new 
therapeutic options to patients. For instance, in Canada, 
oncology drugs are adopted at the highest thresholds of 
acceptability.30 Some exceptions have also been made in 
the UK, escaping the rigid application of cost-effectiveness 
thresholds because of the introduction of new criteria for 
appraising EOL treatments.31 In this regard, a study that 
estimated the plausible cost-effectiveness threshold of the 
National Institute for Health and Care Excellence follow-
ing the application of the EOL criteria suggested that the 
cost-effectiveness threshold could be ~£50,000/QALY.32 
Moreover, the approval of the Cancer Drug Fund is another 
example of an exception made in the UK for paying for 
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expensive oncology medications that have not been recom-
mended for coverage by the National Institute for Health 
and Care Excellence. The fund’s approval, as well as its 
recent renewal, has generated an intense debate regarding 
its lack of support for evidence-based decision making.33 
In conclusion, decisions regarding which drugs to fund to 
treat feared diseases such as cancer sometimes depend on 
political and social acceptability.29
Regarding cancer drugs, in addition to the cost-effectiveness 
thresholds explored in the present study, other factors should 
be considered in the decision-making process about their 
funding by NHS. Priority settings are critical in aligning 
drug funding with national health needs. Once the impor-
tant priority goals are determined, future actions to achieve 
those goals will be identified easily, thereby facilitating the 
decision-making process. Cost opportunity should also be 
considered since, relative to needs, resources are scarce. 
Involving patients and the general population in the decision-
making process is also desirable. However, only a few current 
health care systems have established mechanisms for seeking 
this information from patients or the general population.
This study has several limitations. Most of the associa-
tions included in the study were breast cancer associations, 
which resulted in an overrepresentation of women in our 
patient sample. A convenience sample of the general popu-
lation was taken to guarantee an acceptable response rate. 
Because most of the respondents were employed and had a 
university degree, plausible problems related to a misunder-
standing of the questionnaire were minimized.
Even though the sample size of the study is questionable, 
it should be considered that most methodologists openly 
recognize the lack of standards for sample size in qualitative 
studies. There is a vast range of sample sizes for all research 
designs, with the most common sample size being between 
20 and 30 interviews.34
Finally, to make better informed decisions, additional 
information such as burden of illness, budget impact based 
on the number of patients expected to treat, and whether the 
new treatment addressed an unmet need should be added to 
each of the presented scenarios.
Despite these limitations, the strength of this study lies 
in adapting a similar methodology used in other oncology 
studies and in including a broader number of stakeholders 
who may have an influence on the decision-making process. 
The use of the QALY as a measure of health benefits also 
allowed comparisons to be made. Moreover, the simple 
and indirect approach used in this study to obtain cost-
effectiveness thresholds in the form of cost per QALY is 
also a strength of this study and can be translated to other 
research areas.
Conclusion
In conclusion, decisions regarding the prioritization and 
selection of new cancer treatments based on their cost- 
effectiveness require using a predefined threshold to interpret 
study results. These thresholds should reflect the society’s 
opinion regarding the willingness to pay for specific out-
comes. Discrepancies in perceptions among oncologists, 
health care policy makers, patients, and the general popu-
lation should be considered when establishing thresholds 
for new oncology treatments, which thus merit further 
investigation.
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